Trial Profile
A phase 2 study to evaluate the efficacy and tolerability of adjuvant concurrent temozolomide + radiotherapy followed by rindopepimut in patients with newly diagnosed glioblastoma multiforme expressing epidermal growth factor receptor (EGFR) vIII
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2012
Price :
$35
*
At a glance
- Drugs Rindopepimut (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms ACT-II; ACTIVATE
- 15 Nov 2012 3-Year survival data will be presented at the Society of Neuro-Oncology's 17th Annual Scientific Meeting and Education Day, according to a Celldex Therapeutics media release.
- 05 Nov 2012 Updated survival data will be presented at the Society of Neuro-Oncology's 17th Annual Scientific Meeting and Education Day according to a Celldex Therapeutics media release.
- 04 Jan 2012 Status changed from active, no longer recruiting to completed, according to a Celldex media release.